V2ACT Therapeutics on Track to Launch Phase I/IIa Pancreatic Cancer Trial, Following FDA Nod
BioSpace
DECEMBER 10, 2020
Food and Drug Administration (FDA) has given the greenlight for V2ACT Therapeutics to proceed with a Phase I/IIa clinical trial of its investigational treatment for newly diagnosed surgically resectable pancreatic cancer.
Let's personalize your content